[ad_1]
This new formulation, Trastuzumab Subcutan, was approved by the Food and Drug Administration (BPOM) on May 23, 2018.
"The approval of this subcutaneous Trastuzumab is excellent news for patients , this formulation, the process of giving the drug as a whole is getting faster, because the timing of the drug is much shorter, "said Binay Swarup, medical director of Roche Indonesia, at a press conference at the Westin Hotel Jakarta. Trastuzumab previously available only in intravenous formulations, is a drug that has been used for the management of HER2-positive bad cancer.
This drug has had an impact in improving the survival rate of salvation (19659003) The subcutaneous formulation of Trastuzumab provides more comfort to the patient and reduces overall health costs compared to the average. old formula used with standard intravenous infusion (IV).
The subcutaneous trastuzumab is sold in Indonesia at a price of 14 million rupees for a single treatment, unfortunately this drug is not yet included in the funding of BPJS
"Trastuzumab Subcutan is still used by patients and public companies of the Dharmais Cancer Hospital. Currently, she is still subject to registration at BPJS, "said Professor Abdul Kadir, director of Cancer Hospital Dharmais.
As is known, HER2-positive bad cancer is the most aggressive bad cancer.There are 22.8% of women Indonesia, diagnosed with bad cancer, has a Her2 type -positive
[ad_2]
Source link
